The once distinct medical device segments of glucose monitoring and heart surgery now routinely meet up in the intensive care unit, and the recent deal between Edwards Lifesciences Corp. and DexCom Inc. makes the union official. [See Deal] In a deal announced in November, Edwards, a leader in the cardiac surgery market, gained exclusive rights in the hospital market to continuous glucose monitoring technology developed by DexCom.
Glucose monitoring isn’t just for the management of diabetes any more. Now it’s a strategy to improve outcomes following many...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?